03/03
2022
Suzhou Leadsynbio has Completed the Financing C Round of RMB400 Million
03/03
At the beginning of February, Leadsynbio （or “the company”）, an enterprise with considerable attention in the field of synthetic biology, announced the completion of C-round financing which is over RMB400 million. The C round is co-lead invested by GL Ventures and Sherpa Healthcare Partners, Asia Green Fund (AGF) is one of the co-investors as the old shareholder. The company indicated the financing will be used to accelerate the commercialization of existing products, further improve the research and development pipeline and the expansion of Hunan production base.
Leadsynbio is a high-tech company that changes the production mode of exsitingchemical and biological products through synthetic biology technology. Its products cover pharmaceuticals, health products and agricultural products. The company has a comprehensive synthetic biology technology platform and a research and development team of more than 100 people. It has development&D centers in Suzhou Industrial Park and San Francisco, USA, respectively, the company has an industrialization base in Changde, Hunan.
Dr. Xie Xinkai, the founder and CEO of the company, has nearly 20 years of experience in research and industrial transformation of synthetic biology. Dr. Xie is a graduate of the University of California, Los Angeles, and learn from Professor YiTang and a postdoctoral from Professor Jay Keasling of the University of Berkeley. Professor Keasling is the inventor of artemisinin biosynthesis and one of the founders of synthetic biology. Dr. Xie, as the first inventor of the biosynthesis of simvastatin, a lipid-lowering drug, won the 2012 Presidential Green Chemistry Challenge Award in the United States. Before backing home, he worked for Codexis, an international leading synthetic biology enterprise, and participated in projects of many multinational pharmaceutical and energy enterprises during his time.
Leadsynbio has already achieved patch production of a number of products with the innovative green technology, , and has developed more than 20 new products in its pipelines. In April 2021, AGF has invested in Leadsynbio for the first time to grow the company.
Dr. Xie said: "I am grateful to the investors for their recognition and support to Leadsynbio. The company relies on advanced platform technology, abundant product pipelines and efficient team cooperation to continuously strengthen the construction of synthetic biology platform and the ability of industrialization landing, seize the market opportunity of high-speed development, continuously launch products with innovative green technology on the basis of existing 20+ products, expand the application boundary of synthetic biology, and accelerate the achievement of China's 2030 peak carbon dioxide emissions and 2060 carbon neutralization targets. "
Leadsynbio is a high-tech company that changes the production mode of exsitingchemical and biological products through synthetic biology technology. Its products cover pharmaceuticals, health products and agricultural products. The company has a comprehensive synthetic biology technology platform and a research and development team of more than 100 people. It has development&D centers in Suzhou Industrial Park and San Francisco, USA, respectively, the company has an industrialization base in Changde, Hunan.
Dr. Xie Xinkai, the founder and CEO of the company, has nearly 20 years of experience in research and industrial transformation of synthetic biology. Dr. Xie is a graduate of the University of California, Los Angeles, and learn from Professor YiTang and a postdoctoral from Professor Jay Keasling of the University of Berkeley. Professor Keasling is the inventor of artemisinin biosynthesis and one of the founders of synthetic biology. Dr. Xie, as the first inventor of the biosynthesis of simvastatin, a lipid-lowering drug, won the 2012 Presidential Green Chemistry Challenge Award in the United States. Before backing home, he worked for Codexis, an international leading synthetic biology enterprise, and participated in projects of many multinational pharmaceutical and energy enterprises during his time.
Leadsynbio has already achieved patch production of a number of products with the innovative green technology, , and has developed more than 20 new products in its pipelines. In April 2021, AGF has invested in Leadsynbio for the first time to grow the company.
Dr. Xie said: "I am grateful to the investors for their recognition and support to Leadsynbio. The company relies on advanced platform technology, abundant product pipelines and efficient team cooperation to continuously strengthen the construction of synthetic biology platform and the ability of industrialization landing, seize the market opportunity of high-speed development, continuously launch products with innovative green technology on the basis of existing 20+ products, expand the application boundary of synthetic biology, and accelerate the achievement of China's 2030 peak carbon dioxide emissions and 2060 carbon neutralization targets. "